Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,613 signal articles · 101 in last 24h · 155,521 total before filter · latest 2h ago
101last 24h
848last 7d
142● bullish (7d)
90● bearish (7d)
214publishers
AllMacro191Earnings105M&A124Regulatory20Product21Analyst19
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
Albemarle Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Albemarle Q2 Earnings Call Highlights

Albemarle (NYSE:ALB) reported higher second-quarter sales, earnings and cash generation as lithium pricing improved and its specialties business benefited from stronger pricing and volumes. Second-quarter net sales rose 31% from a year earlier to $1.7 billion, while adjusted EBITDA more than double

Ziff Davis Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Ziff Davis Q2 Earnings Call Highlights

Ziff Davis (NASDAQ:ZD) said its second-quarter results reflected continued pressure in search-driven advertising businesses, partially offset by growth in several operating areas, while the company moved to reshape its capital structure following the sale of its Connectivity business. During the qu

BlackSky Technology (BKSY) Could Be 31% Undervalued As Strong Earnings Back Guidance
Simply Wall St.49d agoneutral
BlackSky Technology (BKSY) Could Be 31% Undervalued As Strong Earnings Back Guidance

BlackSky Technology (BKSY) stock is in focus after the company reported second quarter 2026 results that combined 50.1% year over year revenue growth, a narrower loss, and reaffirmed full year revenue guidance of US$130 million to US$150 million. See our latest analysis for BlackSky Technology. BlackSky Technology's latest earnings announcement and reaffirmed revenue guidance have coincided with a sharp rebound in the stock, with a 1-day share price return of 10.37% and 7-day share price...

Xenon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Xenon Pharmaceuticals Q2 Earnings Call Highlights

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter. Chief Executive Offi

Wendy's Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Wendy's Q2 Earnings Call Highlights

Wendy's (NASDAQ:WEN) reported weaker second-quarter results as U.S. traffic declines, pressure on franchisee economics and what new Chief Executive Officer Bob Wright described as erosion in the brand’s quality and value proposition weighed on performance. Global systemwide sales declined 6.5% on a

Warner Bros. Discovery Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Warner Bros. Discovery Q2 Earnings Call Highlights

Warner Bros. Discovery (NASDAQ:WBD) said its streaming segment surpassed $3 billion in quarterly revenue for the first time in the second quarter of 2026, as HBO Max benefited from subscriber growth, engagement and advertising monetization. President and Chief Executive Officer David Zaslav said st

Versant Q2 Earnings Call Highlights
MarketBeat49d agoneutral
Versant Q2 Earnings Call Highlights

Versant (NASDAQ:VSNT) reported second-quarter revenue of $1.64 billion, down 4% from the prior-year period, while adjusted EBITDA rose 3% to $624 million as growth in advertising and digital platforms helped offset continued pressure in linear television distribution. Chief Executive Officer Mark L